Publications

This report provides a framework and proposes options for governance that would align the Prostheses List processes with those of other health technology assessment processes within the Government. It was developed by Adelaide Health Technology Assessment, under the Prostheses List Reform program.

This report outlines the pre-listing assessment framework and governance structure for the Prostheses List. It also addresses Ernst & Young, and Adelaide Health Technology Assessment options and recommendations.

This review provides options and recommendations for the future governance of the Prostheses List. It was developed by Ernst & Young under the Department’s Prostheses List Reform program.

This report is of gifts given to officers of the Department of Health that are valued over $100, as at 31 December 2022.

The experiences of older people in residential aged care provides vital insights into the quality of care and services they receive. Residents’ Experience Survey (formerly Consumer Experience Interviews) results provide residential aged care homes with useful data to identify areas for improvement.

Use this form to help transition a patient’s care to a new physician, where there are no other changes to their treatment or eligibility for the Life Saving Drugs Program (LDSP).

This guidance document outlines our process and associated timelines to consider medicines seeking funding through the LSDP. It helps sponsors to prepare an application to make an ultra-rare disease medicine available on the LSDP.

This fact sheet provides information to help support the correct billing of Medicare Benefits Schedule Items (MBS) 18222 and 18225 for regional or field nerve blocks.

Health professionals can print this fact sheet and give it to patients who are starting treatment under the Life Saving Drugs Program.

This fact sheet gives answers to common questions about the role of pharmacies and authorised persons in managing Life Saving Drugs Program (LSDP) medicines.

This fact sheet gives answers to common questions about the role of treating physicians in prescribing Life Saving Drugs Program (LSDP) medicines.

This weekly report provides a snapshot of data on the impact of COVID-19 in residential aged care facilities nationally. The report includes data on the number of services impacted and number of staff and resident cases, as well as workforce, testing and PPE provided to affected services.

This fact sheet provides our position on the hospital treatment certification.

This document looks at the improvements to the National Framework for Alcohol, Tobacco and other Drug Treatment. It looks at improving processes for communication, coordination, and collaboration (CCC) between and amongst alcohol and other drug (AOD) treatment funders.

This report lists the percentage of people who have self identified as Indigenous who have been vaccinated against COVID-19, by SA4. The percentages are further broken down by geographic regions and whether they've had one dose or are fully vaccinated.

These reports list the percentage of people who have been vaccinated against COVID-19 by local government area (LGA).

This presentation, delivered on 25 January 2023, contains an update to Australia's COVID-19 vaccine rollout.

This data file contains statistical data about Australia's COVID-19 vaccinations.

This suite of materials for the 'Japanese encephalitis virus' campaign encourages Australians to cover up, use insect repellent and use a screen or net.

This poster provides key differences between each COVID-19 vaccine approved for use in Australia as per the Australian Technical Advisory Group on Immunisation (ATAGI) guidelines.

This fact sheet explains the separate funding class for individuals who enter residential care for the purpose of receiving palliative care.

This infographic issued on 27 January 2023 provides a weekly traffic light report of the coronavirus (COVID-19) situation across Australia.

This Pompe disease review considered alglucosidase alfa. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health consumers.

This Pompe disease review considered alglucosidase alfa. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations.

This MPS II review considered idursulfase. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health consumers.